FDA grants Priority Review to Roche ’s emicizumab for haemophilia A with inhibitors

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for emicizumab prophylaxis (preventative) as a once-weekly subcutaneous treatment for adults, adolescents and children with haemophilia A with factor VIII inhibitors.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news